ANGO (AngioDynamics, Inc.) — AI Stock Analysis & Recommendation

Research of September 7, 2026 · Healthcare / Surgical & Medical Instruments & Apparatus

TradeFlare's AI research teams rate ANGO a HOLD. The latest price is $12.13.

The research plan

• Entry: $15.20
• Time horizon: days

The current market and stock setup does not warrant a buy.

Why

The current market and stock setup does not warrant a buy. Catalysts to watch: Continued positive retail and analyst sentiment in the MedTech sector; Potential for new product commercialization to drive future revenue; Any significant positive news regarding margin improvement or cost reduction. Key risks: Persistent unprofitability and high debt-to-equity ratio pose significant financial risk; Technicals show weakening momentum and lack of volume conviction, despite an uptrend; High risk score and only one bullish directional team make this a speculative play.

What could push ANGO higher

• Continued positive retail and analyst sentiment in the MedTech sector.
• Potential for new product commercialization to drive future revenue.
• Any significant positive news regarding margin improvement or cost reduction.

Key risks for ANGO

• Persistent unprofitability and high debt-to-equity ratio pose significant financial risk.
• Technicals show weakening momentum and lack of volume conviction, despite an uptrend.
• High risk score and only one bullish directional team make this a speculative play.

What each AI research team found

Fundamental team: Neutral · valuation: speculative

AngioDynamics presents a speculative case with strong gross margins and positive revenue growth offset by persistent unprofitability and a very high debt burden. While there's potential upside indicated by analyst targets, the fundamental financial health remains a significant concern, leading to a neutral verdict with moderate conviction.

• AngioDynamics exhibits persistent unprofitability with negative net and operating margins, despite strong gross margins (54.6%).
• The company carries a very high debt-to-equity ratio (6.41), signaling significant financial risk.
• Revenue growth is positive (8% YoY) but decelerating, and forward P/E is negative, indicating expected continued losses.

Technical team: Neutral

The analysis presents a neutral outlook due to conflicting signals. While the Trend Analyst identifies an uptrend, Volume and Momentum indicators suggest weakening conviction and potential for a pullback. Price is consolidating at resistance, making a breakout uncertain and increasing the risk of a short-term decline.

• Price is in a short-to-medium term uptrend, trading above MA20 and MA50, but is currently testing resistance at $15.80.
• Volume has been below average, lacking conviction, and a significant spike on a down day suggests potential distribution near resistance.
• Momentum indicators are mixed to bearish, with MACD and Stochastic showing weakening upward momentum as price approaches resistance.

Sentiment team: Bullish

The overall sentiment for ANGO is cautiously bullish, driven by strong MedTech growth prospects, recent positive earnings, and analyst optimism. While concerns around margin pressure and execution risks persist, the improving sentiment momentum and clear catalysts suggest a positive outlook, especially given the oversold RSI signal.

• ANGO news coverage is largely neutral, with a slight negative average headline score, driven by a focus on MedTech growth as a key driver, but tempered by concerns over margin pressure, tariffs, and ongoing losses. (Score: -0.062)
• Retail sentiment for ANGO is largely positive, driven by strong MedTech growth, recent earnings beats, and bullish analyst ratings, though concerns about margin pressure and execution risks persist. (Score: 0.35)
• AngioDynamics exhibits a predominantly positive analyst sentiment driven by strong MedTech growth, recent earnings beats, and significant upside potential indicated by price targets, though some conflicting ratings and increasing short interest warrant...

Risk team: High

ANGO presents a high-risk profile due to significant historical drawdowns, high volatility, and substantial execution risks associated with its product commercialization and manufacturing transition. The company's financial sustainability is also a concern given its cash burn and leverage, amplified by sector-specific challenges in MedTech/Biotech.

• Deep Drawdown and High Volatility: The stock has experienced a significant -76.9% drawdown over the past year with 60-day annualized volatility at 39.1%, indicating substantial historical price swings and potential for large losses.
• Turnaround Execution and Manufacturing Transition Risk: The company's success depends on the commercial scaling of new products and a transition to outsourced manufacturing, both carrying significant execution and operational risks.
• Cash Burn and Financial Sustainability: Ongoing losses, negative operating cash flow in the latest quarter, and a high debt-to-equity ratio (6.414) raise concerns about financial sustainability and runway, especially in the MedTech/Biotech sector.

ANGO at a glance

Market value	$511.8M
Revenue growth (year over year)	8.2%
Profit margin	-10.1%
Debt / equity	0.00

Every AI call on ANGO since July 16, 2026, and what happened next (4 calls) →

Research of September 7, 2026 · AI-generated analysis for educational purposes, can be wrong, not financial advice.